Speaker Pelosi’s Drug Pricing Plan Could Result in 56 Fewer New Medicines Over 10 YearsNov 21 2019
Speaker Nancy Pelosi’s Lower Drug Costs Now Act of 2019, H.R.3, could result in at least 56 fewer new medicines for patients over 10 years, according to a new analysis from economic consulting firm Vital Transformation. The study examined the impact of foreign reference pricing provisions in H.R.3 on treatments and cures from small, emerging U.S. biotech companies that rely on venture capital to finance their research and development. The analysis was commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA).
|
|
Green Energy Solutions Unleashed Through New PartnershipNov 21 2019
BIO and LCFC efforts will promote state-based low carbon fuel policies.
|
|
America’s Bioeconomy Plays Critical Role in Feeding, Fueling, and Healing the WorldOct 22 2019
“What has set the U.S. biotech sector apart has been thoughtful, bipartisan public policy approaches that create a favorable climate in which to undertake the lengthy and risky job of investing in and developing the next biotech breakthroughs.”
|
|
Proposed CFIUS Regulations Threaten Investment in America’s Life SciencesOct 21 2019
“BIO fully supports the role of CFIUS in ensuring appropriate national security screening of certain foreign investments, but any rules must not discourage the entrepreneurial spirit that has made America the global leader in biopharmaceutical innovation,” said Tom DiLenge, president of BIO’s Advocacy, Law & Public Policy Division.
|
|
Nonpartisan Budget Experts Warn Speaker Pelosi’s Drug Pricing Bill will Stifle the Development of New MedicinesOct 14 2019
BIO’s President and CEO Jim Greenwood issued the following statement after the Congressional Budget Office released an analysis confirming that H.R. 3 will lead to fewer new medicines for patients.
|
|
Biotechnology Innovation Organization Announces 2021 Leadership TransitionOct 8 2019
The Biotechnology Innovation Organization (BIO) today announced that industry veteran Jim Greenwood will step down as President and CEO of the world’s largest biotechnology organization after the 2020 election and help transition a new leader to represent the industry globally and to defend innovation from domestic political attacks.
|
|
RFS Proposal Supports Green Energy BreakthroughsOct 4 2019
The Biotechnology Innovation Organization (BIO) today released the following statement on the administration’s proposal on the Renewable Fuel Standard. The following statement may be attributed to Stephanie Batchelor, vice president of BIO's industrial & environmental section:
|
|
New Executive Order Critical to Protecting Patients and Public HealthSep 20 2019
President Trump has signed an executive order focused on spurring the development of new vaccine technologies, prioritizing the production of influenza vaccines and identifying strategies for communicating the importance of influenza vaccination.
|
|
Speaker Pelosi’s Drug Pricing Plan “Crushes the Desperate Hopes of Patients and their Families”Sep 19 2019
Washington, D.C. (September 19, 2019) – Former Congressman Jim Greenwood, the President and CEO of the Biotechnology Innovation Organization (BIO), issued the following... |
|
Administration Undermines Farmers and Rural Economies With Unjustifiable Renewable Fuel Standard WaiversAug 11 2019
Washington, D.C. (August 10, 2019) –The Biotechnology Innovation Organization (BIO) released the following statement on the administration’s decision to issue 31 small refinery exemptions under the Renewable Fuel Standard.
|
